Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Apatinib Combined With S-1 in Advanced NSCLC
NCT03129256Phase 2Completed
- Sponsor
- Changzhou Cancer Hospital of Soochow University
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Changzhou Cancer Hospital of Soochow University. Started Dec 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03129256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129256.